胰腺导管腺癌的免疫治疗——挑战与机遇并存

葛伟玉; 王红霞

doi:10.3969/j.issn.1001-5256.2019.05.005

胰腺导管腺癌的免疫治疗——挑战与机遇并存

DOI: 10.3969/j.issn.1001-5256.2019.05.005

上海交通大学附属第一人民医院肿瘤科

详细信息

中图分类号: R735.9
计量
- 文章访问数: 1641
- HTML全文浏览量: 14
- PDF下载量: 437
- 被引次数: 0
出版历程
- 收稿日期: 2019-03-15
- 出版日期: 2019-05-20

Immunotherapy for pancreatic ductal adenocarcinoma: Challenges and opportunities

Department of Oncology, The First People' s Hospital Affiliated to Shanghai Jiao Tong University

摘要

摘要: 胰腺导管腺癌（PDAC）是胰腺癌中最常见的一种恶性肿瘤类型,且极易发生微转移。尽管近年来恶性肿瘤的免疫治疗取得重大进步,以程序性细胞死亡蛋白-1/程序性死亡配体-1抗体为代表的免疫检查点阻断,彻底改变了非小细胞肺癌、黑色素瘤、尿路上皮癌和肾癌等的临床诊疗。然而,由于PDAC的低免疫原性和独特的肿瘤微环境（TME）,该免疫治疗方案在PDAC中并不尽如人意,PDAC的5年生存率在所有恶性肿瘤中仍为最差。随着对PDAC-TME的研究发展和理解的深入,深度解析免疫系统、肿瘤细胞和基质信号之间高度复杂的相互作用网络,将有助于开发针对PDAC免疫疗法的合理组合。通过阐述PDAC-TME的免疫独特性,探讨PDAC的潜在治疗机会以及相关临床研究进展。
- 癌,胰腺管 /
- 免疫疗法 /
- 调亡调节蛋白质类
Abstract: Pancreatic ductal adenocarcinoma ( PDAC) is the most common type of pancreatic cancer, and its micrometastases are commonly seen in clinical practice. Although great progress has been made in immunotherapy for malignancies in recent years, immune checkpoint blockade focusing on programmed cell death protein 1 ( PD-1) /programmed death-ligand 1 ( PD-L1) has changed the clinical diagnosis and treatment of non-small cell lung cancer, melanoma, urothelial carcinoma, and renal carcinoma. However, the clinical effect of immunotherapy in PDAC is limited by the low immunogenicity and unique tumor microenvironment ( TME) of PDAC. With the research advances in PDAC-TME, an in-depth analysis of the highly complex interaction network between immune system, tumor cell, and matrix signal may help to develop a rational combination of immunotherapies for PDAC. By elaborating on the unique immunological features of PDAC-TME, this article reviews the potential treatment opportunities for PDAC and the advances in clinical research.
- carcinoma, pancreatic ductal /
- immunotherapy /
- programmed cell death proteins

HTML全文

参考文献(71)

[1] TORRE LA, TRABERT B, DESANTIS CE, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68 (4) :284-296.

[2] LIU Q, LIAO Q, ZHAO Y. Chemotherapy and tumor microenvironment of pancreatic cancer[J]. Cancer Cell Int, 2017, 17:68.

[3] ZHENG L, XUE J, JAFFEE EM, et al. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma[J]. Gastroenterology, 2013, 144 (6) :1230-1240.

[4] MENON S, SHIN S, DY G. Advances in cancer immunotherapy in solid tumors[J]. Cancers, 2016, 8 (12) :E106.

[5] ROYAL RE, LEVY C, TURNER K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma[J]. J Immunother, 2010, 33 (8) :828-833.

[6] BRAHMER JR, TYKODI SS, CHOW LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366 (26) :2455-2465.

[7] DUNN GP, OLD LJ, SCHREIBER RD. The three Es of cancer immunoediting[J]. Annu Rev Immunol, 2004, 22:329-360.

[8] PAGURA L, CACERES JM, CARDINALE A, et al. A mammary adenocarcinoma murine model suitable for the study of cancer immunoediting[J]. J Biomed Sci, 2014, 21:52.

[9] RAJA J, LUDWIG JM, GETTINGER SN, et al. Oncolytic virus immunotherapy:Future prospects for oncology[J]. J Immunother Cancer, 2018, 6 (1) :140.

[10] CHOWELL D, MORRIS LGT, GRIGG CM, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy[J]. Science, 2018, 359 (6375) :582-587.

[11] KATSUYA Y, FUJITA Y, HORINOUCHI H, et al. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma[J]. Lung Cancer, 2015, 88 (2) :154-159.

[12] NAKANISHI J, WADA Y, MATSUMOTO K, et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers[J]. Cancer Immunol Immunother, 2007, 56 (8) :1173-1182.

[13] NOMI T, SHO M, AKAHORI T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer[J].Clin Cancer Res, 2007, 13 (7) :2151-2157.

[14] FAY AP, SIGNORETTI S, CALLEA M, et al. Programmed death ligand-1 expression in adrenocortical carcinoma:An exploratory biomarker study[J]. J Immunother Cancer, 2015, 3:3.

[15] STROME SE, DONG H, TAMURA H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma[J]. Cancer Res, 2003, 63 (19) :6501-6505.

[16] WILMOTTE R, BURKHARDT K, KINDLER V, et al. B7-homolog 1 expression by human glioma:A new mechanism of immune evasion[J]. Neuroreport, 2005, 16 (10) :1081-1085.

[17] MCDERMOTT DF, ATKINS MB. PD-1 as a potential target in cancer therapy[J]. Cancer Med, 2013, 2 (5) :662-673.

[18] DONG H, STROME SE, SALOMAO DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis:A potential mechanism of immune evasion[J]. Nat Med, 2002, 8 (8) :793-800.

[19] JIANG Y, LI Y, ZHU B. T-cell exhaustion in the tumor microenvironment[J]. Cell Death Dis, 2015, 6:e1792.

[20] WANG X, TENG F, KONG L, et al. PD-L1 expression in human cancers and its association with clinical outcomes[J].Onco Targets Ther, 2016, 9:5023-5039.

[21] GAO HL, LIU L, QI ZH, et al. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer:A meta-analysis[J]. Hepatobiliary Pancreat Dis Int, 2018, 17 (2) :95-100.

[22] COPPOCK JD, VOLARIC AK, MILLS AM, et al. Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas[J].Hum Pathol, 2018, 82:282-288.

[23] GERLINGER M, ROWAN AJ, HORSWELL S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing[J]. N Engl J Med, 2012, 366 (10) :883-892.

[24] WANG L, MA Q, CHEN X, et al. Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma[J]. World J Surg, 2010, 34 (5) :1059-1065.

[25] CHEN Y, SUN J, ZHAO H, et al. The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer[J]. Onco Targets Ther, 2014, 7:1465-1472.

[26] LOOS M, GIESE NA, KLEEFF J, et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer[J]. Cancer Lett, 2008, 268 (1) :98-109.

[27] GENG L, HUANG D, LIU J, et al. B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression[J]. J Cancer Res Clin Oncol, 2008, 134 (9) :1021-1027.

[28] BIRNBAUM DJ, FINETTI P, LOPRESTI A, et al. Prognostic value of PDL1 expression in pancreatic cancer[J]. Oncotarget, 2016, 7 (44) :71198-71210.

[29] ZHANG CM, LV JF, GONG L, et al. Role of deficient mismatch repair in the personalized management of colorectal cancer[J]. Int J Environ Res Public Health, 2016, 13 (9) :E892.

[30] SHARP JT, LIDSKY MD, DUFFY J, et al. Comparison of two dosage schedules of gold salts in the treatment of rheumatoid arthritis. Relationship of serum gold levels to therapeutic response[J]. Arthritis Rheum, 1977, 20 (6) :1179-1187.

[31] SALEM ME, PUCCINI A, GROTHEY A, et al. Landscape of tumor mutation load, mismatch repair deficiency, and pd-l1expression in a large patient cohort of gastrointestinal cancers[J]. Mol Cancer Res, 2018, 16 (5) :805-812.

[32] CHAMPIAT S, FERTE C, LEBEL-BINAY S, et al. Exomics and immunogenics:Bridging mutational load and immune checkpoints efficacy[J]. Oncoimmunology, 2014, 3 (1) :e27817.

[33] LATSOUDIS H, MASHREGHI MF, GRUN JR, et al. Differential expression of miR-4520a associated with pyrin mutations in familial mediterranean fever (FMF) [J]. J Cell Physiol, 2017, 232 (6) :1326-1336.

[34] KIM ST, KLEMPNER SJ, PARK SH, et al. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types:Lmplications for immunotherapy[J]. Oncotarget, 2017, 8 (44) :77415-77423.

[35] MARISA L, SVRCEK M, COLLURA A, et al. The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors[J]. J Natl Cancer Inst, 2018, 110 (1) :68-77.

[36] WALKER EJ, CARNEVALE J, PEDLEY C, et al. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma[J]. Fam Cancer, 2018.[Epub ahead of print]

[37] KAWAKAMI H, ZAANAN A, SINICROPE FA. Microsatellite instability testing and its role in the management of colorectal cancer[J]. Curr Treat Options Oncol, 2015, 16 (7) :30.

[38] LEMERY S, KEEGAN P, PAZDUR R. First FDA Approval agnostic of cancer site-when a biomarker defines the indication[J]. N Engl J Med, 2017, 377 (15) :1409-1412.

[39] CHANG L, CHANG M, CHANG HM, et al. Microsatellite instability:A predictive biomarker for cancer immunotherapy[J].Appl Immunohistochem Mol Morphol, 2018, 26 (2) :e15-e21.

[40] EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate040) :An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389 (10088) :2492-2502.

[41] PATNAIK A, KANG SP, RASCO D, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors[J]. Clin Cancer Res, 2015, 21 (19) :4286-4293.

[42] WEISS GJ, BLAYDORN L, BECK J, et al. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma[J]. Invest New Drugs, 2018, 36 (1) :96-102.

[43] COOK AM, LESTERHUIS WJ, NOWAK AK, et al. Chemotherapy and immunotherapy:Mapping the road ahead[J]. Curr Opin Immunol, 2016, 39:23-29.

[44] McDONNELL AM, LESTERHUIS WJ, KHONG A, et al. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy[J].Eur J Immunol, 2015, 45 (1) :49-59.

[45] HAYNES NM, van der MOST RG, LAKE RA, et al. Immunogenic anti-cancer chemotherapy as an emerging concept[J]. Curr Opin Immunol, 2008, 20 (5) :545-557.

[46] van der MOST RG, ROBINSON BW, LAKE RA. Combining immunotherapy with chemotherapy to treat cancer[J]. Discov Med, 2005, 5 (27) :265-270.

[47] VONDERHEIDE RH, GLENNIE MJ. Agonistic CD40 antibodies and cancer therapy[J]. Clin Cancer Res, 2013, 19 (5) :1035-1043.

[48] LONG KB, GLADNEY WL, TOOKER GM, et al. IFNgamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma[J]. Cancer Discov, 2016, 6 (4) :400-413.

[49] BEATTY GL, TORIGIAN DA, CHIOREAN EG, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870, 893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma[J]. Clin Cancer Res, 2013, 19 (22) :6286-6295.

[50] MITCHEM JB, BRENNAN DJ, KNOLHOFF BL, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses[J]. Cancer Res, 2013, 73 (3) :1128-1141.

[51] WITKIEWICZ A, WILLIAMS TK, COZZITORTO J, et al. Expression of indoleamine 2, 3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection[J]. J Am Coll Surg, 2008, 206 (5) :849-854, discussion 54-56.

[52] MUNN DH, MELLOR AL. IDO in the tumor microenvironment:Inflammation, counter-regulation, and tolerance[J]. Trends Immunol, 2016, 37 (3) :193-207.

[53] YOUMANS GP, YOUMANS AS. Nonspecific factors in resistance of mice to experimental tuberculosis[J]. J Bacteriol, 1965, 90 (6) :1675-1681.

[54] MASSO-VALLES D, JAUSET T, SERRANO E, et al. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma[J]. Cancer Res, 2015, 75 (8) :1675-1681.

[55] XIA L, SCHRUMP DS, GILDERSLEEVE JC. Whole-cell cancer vaccines induce large antibody responses to carbohydrates and glycoproteins[J]. Cell Chem Biol, 2016, 23 (12) :1515-1525.

[56] LUTZ ER, WU AA, BIGELOW E, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation[J]. Cancer Immunol Res, 2014, 2 (7) :616-631.

[57] SOARES KC, RUCKI AA, WU AA, et al. PD-1/PD-L1blockade together with vaccine therapy facilitates effector Tcell infiltration into pancreatic tumors[J]. J Immunother, 2015, 38 (1) :1-11.

[58] KEENAN BP, SAENGER Y, KAFROUNI MI, et al. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice[J]. Gastroenterology, 2014, 146 (7) :1784-1794. e6.

[59] LE DT, WANG-GILLAM A, PICOZZI V, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenesexpressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer[J]. J Clin Oncol, 2015, 33 (12) :1325-1333.

[60] EBERT PJR, CHEUNG J, YANG Y, et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade[J]. Immunity, 2016, 44 (3) :609-621.

[61] SHINDO Y, HAZAMA S, MAEDA Y, et al. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer[J]. J Transl Med, 2014, 12:175.

[62] POSEY AD Jr, SCHWAB RD, BOESTEANU AC, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma[J]. Immunity, 2016, 44 (6) :1444-1454.

[63] STROMNES IM, SCHMITT TM, HULBERT A, et al. T Cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma[J]. Cancer Cell, 2015, 28 (5) :638-652.

[64] CHMIELEWSKI M, HAHN O, RAPPL G, et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice[J].Gastroenterology, 2012, 143 (4) :1095-1107. e2.

[65] NICHOLLS DJ, WILEY K, DAINTY I, et al. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist[J]. J Pharmacol Exp Ther, 2015, 353 (2) :340-350.

[66] MORTON JP, SANSOM OJ. CXCR2 inhibition in pancreatic cancer:Opportunities for immunotherapy?[J]. Immunotherapy, 2017, 9 (1) :9-12.

[67] STEELE CW, KARIM SA, LEACH JDG, et al. CXCR2 Inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma[J]. Cancer Cell, 2016, 29 (6) :832-845.

[68] ZHANG H, WANG Y, HWANG ES, et al. Interleukin-10:An immune-activating cytokine in cancer immunotherapy[J]. J Clin Oncol, 2016, 34 (29) :3576-3578.

[69] NAING A, PAPADOPOULOS KP, AUTIO KA, et al. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors[J]. J Clin Oncol, 2016, 34 (29) :3562-3569.

[70] KAWAOKA T, OKA M, TAKASHIMA M, et al. Adoptive immunotherapy for pancreatic cancer:Cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1[J]. Oncol Rep, 2008, 20 (1) :155-163.

[71] KONDO H, HAZAMA S, KAWAOKA T, et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes[J]. Anticancer Res, 2008, 28 (1b) :379-387.

施引文献

资源附件(0)

访问统计